Back to search results

Study of RNDP-001 for Idiopathic Parkinson's Disease

This study is testing a new treatment called RNDP-001, which involves implanting stem cells into the brain using a special device. The main goal is to see if RNDP-001 is safe and tolerable for people with idiopathic Parkinson's disease. You might be able to join if you are between 45 and 75 years old, have idiopathic Parkinson's disease, and are healthy enough for surgery. This study is looking to enroll 12 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 12 participants. It is designed to test the safety and tolerability of the RNDP-001 stem cell implant.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and tolerability from the beginning of the study until 15 months after the transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07106021

A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease

Active, Not Recruiting
PHASE1Ages 45–75InterventionalTreatment
Kenai Therapeutics
~12 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:RNDP-001Syringe Front-Loading Device

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability
Measured over Baseline to 15 months post-transplant

Conditions

Idiopathic Parkinson´s Disease
Parkinson's Disease

Explore related trials

Parkinson Disease

NCT07106021

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Keck Medical Center of University of Southern California

    Los Angeles, Californiano site contact published

  • The Ohio State University Wexner Medical Center

    Columbus, Ohiono site contact published

  • University of Arizona

    Tucson, Arizonano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of idiopathic Parkinson's disease consistent with the Movement Disorders Society Clinical Criteria
Age 45 to 75
Medically stable to undergo a surgical procedure

Exclusion

Known Parkinson's disease gene mutation or variant
Previous infusion therapy or surgery for Parkinson's disease
History of allergic reaction or intolerance to an immunotherapeutic agent
Contraindication to MRI
Clinically significant medical conditions likely to interfere with the surgical procedure or study assessments

What this trial measures

  • Safety and TolerabilityBaseline to 15 months post-transplant

    The incidence of adverse events (AEs), serious AEs, AEs of special interest, and patient withdrawals